Home › Companies › VRDN

Viridian Therapeutics

VRDN Lead: Approved 8 Biotech Distilled articles ↓

Ophthalmology Protein

Most recent annual filing: 2026-02-15

Pipeline (6 active programs)

Lumvoa

veligrotug · veligrotug-vvze

Protein Target: IGF-1R

Thyroid Eye Disease Approved intravenous

elegrobart

VRDN-003

Protein Target: IGF-1R

Thyroid Eye Disease Phase 3 subcutaneous

VRDN-006

Protein Target: FcRn

Undisclosed indication Phase 1 subcutaneous
Undisclosed indication

VRDN-008

Protein Target: FcRn

Undisclosed indication Phase 1 subcutaneous
Undisclosed indication Phase 1

Biotech Distilled coverage (8)

2026-06-26 UPDATE: Viridian Therapeutics (VRDN) - Lumvoa Lands Four Days Early
2026-05-26 UPDATE: Viridian Therapeutics (VRDN) - The WuXi Doubling Down 🔒 Paid
2026-05-14 UPDATE: Viridian Therapeutics (VRDN) - Fairmount Doubles Down at $17 🔒 Paid
2026-05-08 UPDATE: Viridian Therapeutics (VRDN) - The Dilution Prints 🔒 Paid
2026-05-06 UPDATE: Viridian Therapeutics (VRDN) - The Chronic TED Redemption Arc, Now With a Dilution Chaser 🔒 Paid
2026-03-31 UPDATE: Viridian Therapeutics (VRDN) REVEAL-1 Update 🔒 Paid
2026-03-01 UPDATE: Viridian (VRDN) - FY25 Update 🔒 Paid
2026-02-05 Viridian Therapeutics (VRDN): Scientific Deep Dive for Veligrotug, Elegrobart, and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.